Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Rodrigo Ramella Munhoz is active.

Publication


Featured researches published by Rodrigo Ramella Munhoz.


Cancer | 2016

Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.

Alain Patrick Algazi; Katy K. Tsai; Alexander N. Shoushtari; Rodrigo Ramella Munhoz; Zeynep Eroglu; Josep M. Piulats; Patrick A. Ott; Douglas B. Johnson; Jimmy Hwang; Adil Daud; Jeffrey A. Sosman; Richard D. Carvajal; Bartosz Chmielowski; Michael A. Postow; Jeffrey S. Weber; Ryan J. Sullivan

Antibodies inhibiting the programmed death receptor 1 (PD‐1) have demonstrated significant activity in the treatment of advanced cutaneous melanoma. The efficacy and safety of PD‐1 blockade in patients with uveal melanoma has not been well characterized.


JAMA Oncology | 2016

Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis

Rodrigo Ramella Munhoz; Allan Andresson Lima Pereira; Andre Deeke Sasse; Paulo M. Hoff; Tiffany A. Traina; Clifford A. Hudis; Ricardo Jose Marques

IMPORTANCE Chemotherapy may result in a detrimental effect on ovarian function and fertility in premenopausal women undergoing treatment for early-stage breast cancer (EBC). To minimize risk of harm to ovarian function and fertility for patients in this setting, careful considerations should be made. Gonadotropin-releasing hormone agonists (GnRHa) have been suggested as an alternative to prevent the loss of ovarian function due to exposure to cytotoxic agents, but GnRHa use for ovarian protection in EBC patients is not fully resolved. OBJECTIVE To determine the effectiveness of GnRHa administered concurrently with chemotherapy for ovarian function preservation. DATA SOURCES PubMed, SCOPUS, and Cochrane databases were searched for studies published between January 1975 and March 2015. The abstracts of the American Society of Clinical Oncology Annual Meeting between 1995 and 2014 and the San Antonio Breast Cancer Symposium between 2009 and 2014 were searched as well. STUDY SELECTION Prospective, randomized, clinical trials addressing the role of ovarian suppression with GnRHa in preventing early ovarian dysfunction in premenopausal women undergoing treatment for EBC were selected. DATA EXTRACTION AND SYNTHESIS Data extraction was performed independently by 2 authors. The methodology and the risk of bias were assessment based on the description of randomization method, withdrawals, and blinding process. MAIN OUTCOMES AND MEASURES Rate of resumption of regular menses after a minimal follow-up period of 6 months following chemotherapy was used as a surrogate to assess the incidence of ovarian dysfunction. Additional secondary outcomes included hormone levels and number of pregnancies. Risk ratio estimates were calculated based on the number of evaluable patients. Analyses were conducted using a random effect model. RESULTS Seven studies were included in this analysis, totaling 1047 randomized patients and 856 evaluable patients. The use of GnRHa was associated with a higher rate of recovery of regular menses after 6 months (odds ratio [OR], 2.41; 95% CI, 1.40-4.15; P = .002) and at least 12 months (OR, 1.85; 95% CI, 1.33-2.59; P < .001) following the last chemotherapy cycle. The use of GnRHa was also associated with a higher number of pregnancies (OR, 1.85; 95% CI, 1.02-3.36; P = .04), although this outcome was not uniformly reported and fertility or rate of pregnancy was not the primary outcome in any of the trials. CONCLUSIONS AND RELEVANCE Gonadotropin-releasing hormone agonists given with chemotherapy was associated with increased rates of recovery of regular menses in this meta-analysis. Evidence was insufficient to assess outcomes related to GnRHa and ovarian function and fertility and needs further investigation.


Cancer | 2016

The efficacy of anti-PD-1 agents in acral and mucosal melanoma

Alexander N. Shoushtari; Rodrigo Ramella Munhoz; Deborah Kuk; Patrick A. Ott; Douglas B. Johnson; Katy K. Tsai; Suthee Rapisuwon; Zeynep Eroglu; Ryan J. Sullivan; Jason J. Luke; Tara C. Gangadhar; April K. Salama; Varina Clark; Clare Burias; Igor Puzanov; Michael B. Atkins; Alain Patrick Algazi; Antoni Ribas; Jedd D. Wolchok; Michael A. Postow

Therapeutic antibodies against programmed cell death receptor 1 (PD‐1) are considered front‐line therapy in metastatic melanoma. The efficacy of PD‐1 blockade for patients with biologically distinct melanomas arising from acral and mucosal surfaces has not been well described.


Oncologist | 2016

Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis

Deborah Kuk; Alexander N. Shoushtari; Christopher A. Barker; Katherine S. Panageas; Rodrigo Ramella Munhoz; Parisa Momtaz; Charlotte E. Ariyan; Mary Sue Brady; Daniel G. Coit; Kita Bogatch; Margaret K. Callahan; Jedd D. Wolchok; Richard D. Carvajal; Michael A. Postow

BACKGROUND Subtypes of melanoma, such as mucosal, uveal, and acral, are believed to result in worse prognoses than nonacral cutaneous melanoma. After a diagnosis of distant metastatic disease, however, the overall survival of patients with mucosal, uveal, acral, nonacral cutaneous, and unknown primary melanoma has not been directly compared. MATERIALS AND METHODS We conducted a single-center, retrospective analysis of 3,454 patients with melanoma diagnosed with distant metastases from 2000 to 2013, identified from a prospectively maintained database. We examined melanoma subtype, date of diagnosis of distant metastases, age at diagnosis of metastasis, gender, and site of melanoma metastases. RESULTS Of the 3,454 patients (237 with mucosal, 286 with uveal, 2,292 with nonacral cutaneous, 105 with acral cutaneous, and 534 with unknown primary melanoma), 2,594 died. The median follow-up was 46.1 months. The median overall survival for those with mucosal, uveal, acral, nonacral cutaneous, and unknown primary melanoma was 9.1, 13.4, 11.4, 11.7, and 10.4 months, respectively. Patients with uveal melanoma, cutaneous melanoma (acral and nonacral), and unknown primary melanoma had similar survival, but patients with mucosal melanoma had worse survival. Patients diagnosed with metastatic melanoma in 2006-2010 and 2011-2013 had better overall survival than patients diagnosed in 2000-2005. In a multivariate model, patients with mucosal melanoma had inferior overall survival compared with patients with the other four subtypes. CONCLUSION Additional research and advocacy are needed for patients with mucosal melanoma because of their shorter overall survival in the metastatic setting. Despite distinct tumor biology, the survival was similar for those with metastatic uveal melanoma, acral, nonacral cutaneous, and unknown primary melanoma. IMPLICATIONS FOR PRACTICE Uveal, acral, and mucosal melanoma are assumed to result in a worse prognosis than nonacral cutaneous melanoma or unknown primary melanoma. No studies, however, have been conducted assessing the overall survival of patients with these melanoma subtypes starting at the time of distant metastatic disease. The present study found that patients with uveal, acral, nonacral cutaneous, and unknown primary melanoma have similar overall survival after distant metastases have been diagnosed. These findings provide information for oncologists to reconsider previously held assumptions and appropriately counsel patients. Patients with mucosal melanoma have worse overall survival and are thus a group in need of specific research and advocacy.


The Journal of Thoracic and Cardiovascular Surgery | 2017

Pulmonary metastasectomy with therapeutic intent for soft-tissue sarcoma

Neel P. Chudgar; Murray F. Brennan; Rodrigo Ramella Munhoz; Peter R. Bucciarelli; Kay See Tan; Sandra P. D'Angelo; Manjit S. Bains; Matthew Bott; James Huang; Bernard J. Park; Valerie W. Rusch; Prasad S. Adusumilli; William D. Tap; Samuel Singer; David R. Jones

Objective: Soft‐tissue sarcoma is a heterogeneous disease that frequently includes the development of pulmonary metastases. The purpose of this study is to determine factors associated with improved survival among patients with soft‐tissue sarcoma to help guide selection for pulmonary metastasectomy. Methods: We reviewed a prospectively maintained database and identified 803 patients who underwent pulmonary metastasectomy for metastatic soft‐tissue sarcoma between September 1991 and June 2014; of these, 539 patients undergoing 760 therapeutic‐intent pulmonary metastasectomies were included. Clinicopathologic variables and characteristics of treatment were examined. The outcomes of interest were overall survival and disease‐free survival. Survival was estimated with the Kaplan‐Meier method and compared between variables with the log‐rank test. Factors associated with hazard of death and recurrence were identified via the use of univariable and multivariable Cox proportional hazards models. Results: Median overall survival was 33.2 months (95% confidence interval, 29.9–37.1), and median disease‐free survival was 6.8 months (95% confidence interval, 6.0–8.0). In multivariable analyses, leiomyosarcoma histologic subtype (P = .007), primary tumor size ≤10 cm (P = .006), increasing time from primary tumor resection to development of metastases (P < .001), solitary lung metastasis (P = .001), and minimally invasive resection (P = .023) were associated with lower hazard of death. Disease‐free interval ≥1 year (P = .002), and 1 pulmonary metastasis (P < .001) were associated with lower hazard of disease recurrence. Conclusions: In a large single‐institution study, primary tumor histologic subtype and size, numbers of pulmonary metastases, disease‐free interval, and selection for minimally invasive resection are associated with increased survival in patients undergoing pulmonary metastasectomy for soft‐tissue sarcoma.


Oncologist | 2015

A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas

Rodrigo Ramella Munhoz; Sandra P. D’Angelo; Mrinal M. Gounder; Mary Louise Keohan; Ping Chi; Richard D. Carvajal; Samuel Singer; Aimee M. Crago; Jonathan Landa; John H. Healey; Li-Xuan Qin; Meera Hameed; Marietta O. Ezeoke; Arun S. Singh; Mark Agulnik; Bartosz Chmielowski; Jason J. Luke; Brian A. Van Tine; Gary K. Schwartz; William D. Tap; Mark A. Dickson

LESSONS LEARNED Our results highlight some of the challenges in the management of soft tissue sarcomas, which requires close cooperation between surgeons and medical oncologists and a careful selection of patients. The incidence of hepatotoxicity was a concerning finding and had been previously reported in patients treated with pazopanib.Although pharmacokinetic analysis was not part of this study, concomitant treatment with pazopanib has been recently reported to increase docetaxel exposure, which may explain the increased toxicity of combination regimens. It remains possible that lower doses of combined gemcitabine, docetaxel, and pazopanib may be tolerable. However, caution should be exercised in future trials investigating similar combinations. BACKGROUND For extremity soft tissue sarcomas (STS), surgical resection remains the standard of care, and the addition of chemotherapy is controversial. This was a phase Ib/II trial of neoadjuvant therapy for patients with STS. METHODS Patients with high grade, extremity STS of >8 cm and amenable to definitive resection were treated with up to four 21-day cycles of 900 mg/m(2) gemcitabine on days 1 and 8, 75 mg/m(2) docetaxel on day 8, and 400 mg of pazopanib daily (GDP), followed by surgery and, if indicated, radiation therapy. Primary and secondary endpoints (phase Ib portion) were the safety and rate of pathologic response. RESULTS The trial was discontinued because of slow accrual after inclusion of five patients (leiomyosarcoma: two; undifferentiated pleomorphic sarcoma: three). Two patients completed four treatment cycles: one underwent surgery and one had insufficient response and received additional therapies. Three patients discontinued treatment because of toxicity. Grade 3 adverse events included hypertension, fatigue, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) elevation, hoarseness, and myelotoxicity. There were no complete or partial responses. One patient had ≥ 90% pathologic response. Among four patients who underwent resection, three remain free of disease, and one patient eventually relapsed. CONCLUSION GDP combination used in the neoadjuvant setting resulted in significant toxicity; despite pathologic responses, no objective responses occurred.


Oncology | 2015

Outcomes of Systemic Therapy for Patients with Metastatic Angiosarcoma

Sandra P. D'Angelo; Rodrigo Ramella Munhoz; Deborah Kuk; Johnathan Landa; Eliza Woodward Hartley; Michael Bonafede; Mark A. Dickson; Mrinal M. Gounder; Mary Louise Keohan; Aimee M. Crago; Cristina R. Antonescu; William D. Tap

Background: Angiosarcomas (AS) are rare tumors of vascular origin with a variable behavior and overall poor prognosis. We sought to assess the outcomes of patients treated for metastatic disease. Methods: We performed a retrospective analysis of 119 patients treated for metastatic AS. Outcomes and efficacy measurements of the first and subsequent lines of treatment were analyzed. Results: Median age was 61 years, and the most frequent primary sites were chest wall/breast (31%), viscera (22%) and head/neck (20%). Seventy-three (61%) and 46 (39%) patients received ≥2 and ≥3 lines of therapy, respectively. The most commonly used agents included taxanes and anthracyclines. Median overall survival was 12.1 months. Median times to tumor progression were 3.5 months for first line, 3.7 months for second line and 2.7 months for third line. Among 48 patients evaluable per RECIST, the overall response rate to first line was 30% and <10% in subsequent lines. Doxorubicin, liposomal doxorubicin and taxanes resulted in similar response rates and survival, and there was no apparent benefit for combination chemotherapy. Conclusion: Despite reasonable response rates in the first-line setting, benefit from systemic therapy is short-lived in metastatic AS, and outcomes are poor. Doxorubicin, liposomal doxorubicin and taxanes are reasonable and appropriate choices for monotherapy.


Nature | 2018

High response rate to PD-1 blockade in desmoplastic melanomas

Zeynep Eroglu; Jesse M. Zaretsky; Siwen Hu-Lieskovan; Dae Won Kim; Alain Patrick Algazi; Douglas B. Johnson; Elizabeth Liniker; Ben Kong; Rodrigo Ramella Munhoz; Suthee Rapisuwon; Pier Federico Gherardini; Bartosz Chmielowski; Xiaoyan Wang; I. Peter Shintaku; Cody Wei; Jeffrey A. Sosman; Richard W. Joseph; Michael A. Postow; Matteo S. Carlino; Wen-Jen Hwu; Richard A. Scolyer; Jane L. Messina; Alistair J. Cochran; Antoni Ribas

Desmoplastic melanoma is a rare subtype of melanoma characterized by dense fibrous stroma, resistance to chemotherapy and a lack of actionable driver mutations, and is highly associated with ultraviolet light-induced DNA damage. We analysed sixty patients with advanced desmoplastic melanoma who had been treated with antibodies to block programmed cell death 1 (PD-1) or PD-1 ligand (PD-L1). Objective tumour responses were observed in forty-two of the sixty patients (70%; 95% confidence interval 57–81%), including nineteen patients (32%) with a complete response. Whole-exome sequencing revealed a high mutational load and frequent NF1 mutations (fourteen out of seventeen cases) in these tumours. Immunohistochemistry analysis from nineteen desmoplastic melanomas and thirteen non-desmoplastic melanomas revealed a higher percentage of PD-L1-positive cells in the tumour parenchyma in desmoplastic melanomas (P = 0.04); these cells were highly associated with increased CD8 density and PD-L1 expression in the tumour invasive margin. Therefore, patients with advanced desmoplastic melanoma derive substantial clinical benefit from PD-1 or PD-L1 immune checkpoint blockade therapy, even though desmoplastic melanoma is defined by its dense desmoplastic fibrous stroma. The benefit is likely to result from the high mutational burden and a frequent pre-existing adaptive immune response limited by PD-L1 expression.


Rare Tumors | 2013

Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas.

Rodrigo Ramella Munhoz; Juliana Florinda de Mendonça Rego; Anezka Rubim de Celis Ferrari; Maria Ignez Braghiroli; Giovanni M. Bariani; Paulo M. Hoff; Frederico Costa; Tulio Pfiffer; Rachel P. Riechelmann

Extrapulmonary poorly differentiated neuroendocrine carcinoma (PDNEC) is a rare and highly aggressive neoplasm for which the optimal chemotherapy remains unclear. The objective of this study was to evaluate the outcomes of patients with PDNEC treated with cisplatin and irinotecan (IP) and perform a review of the literature. From 2008 to 2012, patients with advanced PDNEC (Ki67≥20%) who received the IP combination were selected for analysis. Radiologic responses were determined through Response Evaluation Criteria In Solid Tumors criteria. Twenty-eight patients were included. The median age at diagnosis was 57 years and the most common presentation was pancreatic PDNEC. Twenty-five patients (89%) received chemotherapy with cisplatin and irinotecan and three received carboplatin and irinotecan. Forty-six percent of the patients achieved objective response and the median time to tumor progression was 3.7 months. The median overall survival was 11.7 months. Thirteen patients (46%) had treatment interruptions or dose reductions due to grade 3/4 toxicity. This retrospective cohort of advanced extrapulmonary PDNEC patients suggests that the IP combination is feasible and resulted in similar response rate and median survival to other treatments previously reported.


F1000Research | 2016

Recent advances in understanding antitumor immunity

Rodrigo Ramella Munhoz; Michael A. Postow

The term “antitumor immunity” refers to innate and adaptive immune responses which lead to tumor control. Turning the immune system into a destructive force against tumors has been achieved in a broad range of human cancers with the use of non-specific immunotherapies, vaccines, adoptive-cell therapy, and, more recently with significant success, through blockade of immune checkpoints. Nevertheless, the efficacy of these approaches is not universal, and tools to identify long-term responders and primarily refractory patients are warranted. In this article, we review recent advances in understanding the complex mechanisms of antitumor immunity and how these developments can be used to address open questions in a setting of growing clinical indications for the use of immunotherapy.

Collaboration


Dive into the Rodrigo Ramella Munhoz's collaboration.

Top Co-Authors

Avatar

Michael A. Postow

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Alexander N. Shoushtari

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Paulo M. Hoff

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Douglas B. Johnson

Vanderbilt University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Richard D. Carvajal

Columbia University Medical Center

View shared research outputs
Top Co-Authors

Avatar

William D. Tap

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Zeynep Eroglu

City of Hope National Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Antoni Ribas

University of California

View shared research outputs
Researchain Logo
Decentralizing Knowledge